Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
PTD-DBM targets the CXXC5-Dvl interaction to reactivate Wnt signaling for hair regrowth. Mouse data from 2017 showed new follicle formation, but no human clinical trial exists. Community results remain inconsistent; the peptide's own developer pivoted away to a small molecule alternative.
500mcg · Daily
Summary: Add 0mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 500mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | Daily |
| Moderate | 1mg | Daily |
| Aggressive | 1mg | Daily |
Your first vial is probably going to be a 5 mg lyophilized powder. Reconstitute in 10 mL of sterile water for a 0.5 mg/mL solution, or 5 mL for 1 mg/mL. Draw 1 mL per session with a syringe and apply directly to the scalp (no injection needed). That gives you 500 mcg per application at the lower concentration. A 5 mg vial at daily use lasts about 10 days at 0.5 mg/mL, or 5 days at 1 mg/mL. The thing most beginners miss: this peptide degrades fast once reconstituted. Use it within 14 days at 2 to 8 degrees Celsius. Lyophilized stock should stay at minus 20 degrees. If your vendor shipped without an ice pack, assume the product is compromised. Daily application is the community standard. Weekly dosing (which some guides mistakenly recommend) produces subclinical Wnt exposure. Apply to clean, dry scalp; avoid washing for 4 hours. If you're adding valproic acid, apply PTD-DBM first, wait 15 to 20 minutes, then apply VPA.
Dosing based on Very limited human data: dose based on preclinical research — 9 published references.View all sources →
Cross-check your PTD-DBM reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
PTD-DBM targets the CXXC5-Dvl interaction to reactivate Wnt signaling for hair regrowth. Mouse data from 2017 showed new follicle formation, but no human clinical trial exists. Community results remain inconsistent; the peptide's own developer pivoted away to a small molecule alternative.